Press Releases

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Adeptrix (Beverly, MA, USA) to develop a high throughput COVID-19 antigen test using Adeptrix’s proprietary bead-assisted mass spectrometry (BAMS™) platform. Avacta and Adeptrix will collaborate to develop and manufacture an Affimer-based BAMS coronavirus antigen test that will provide clinicians with a significant expansion o

International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical, biotechnology and device innovation, technology and knowledge from development through commercialization,today announced the next edition of INTERPHEX, previously postponed to July 2020,will now take place April 20-22, 2021 at the Javits Center in New York. “While facing an unprecedented situation, we needed to make tough choices and felt this was the best way to proceed for everyone

Hardy Diagnostics, a 100% employee owned, FDA-licensed manufacturer headquartered in Santa Maria, CA, has been exponentially increasing production volume of products needed for testing during the COVID-19 global pandemic. Specifically, Hardy has increased production of Viral Transport Medium (VTM, Cat. No. R99), a product recommended by the CDC for collection and transportation of specimens from patients suspected of a COVID-19 infection. Hardy has increased production volumes from a few hund

Hardy Diagnostics, a medical device manufacturer based in Santa Maria, California, announced FDA EUA approval on April 24th for a new in vitro diagnostic medical device: Anti-SARS-CoV-2 Rapid Test (Cat. No. RTA0203). This immunoassay is intended for qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human plasma or serum. This test was developed by Autobio Diagnostics Co., Ltd (603658, Shanghai), a publicly-traded, major microbiology medical device

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. (SIX: LONN) today announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future. Under the terms of the agreement, the companies pl

TTP plc, a leading independent technology and product development company, has announced today that it has partnered with ODx (ODx Innovations Ltd), a company committed to developing a system for assessing urinary tract infections (UTIs). The collaboration is focussed on bringing ODx’ system to market through TTP’s Desktop Biology service. The ODx system offers the potential to revolutionise the turnaround time for the assessment of suspected UTIs, reduce the use of anti

Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma of Italy and Kamada Ltd. of Israel - have announced that they are joining forces for the development, manufacturing and clinical distribution of a plasma-derived Anti-SARS-CoV-2 product. The two companies, each known for its cutting-edge biopharma technology capabilities, hope to obtain approval for the clinical treatment of severely ill COVID-19 patients. The initial primary focus of

ProteoGenix, a global leader in antibody production, is pleased to announce the first Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2. "Highly sensitive and specific antibodies are critical for the development of diagnostics, therapeutics, and prophylactics to fight against COVID-19," says Philippe Funfrock, Co-founder and President of ProteoGenix. "The new Human Immune COVID-19 antibody library developed by ProteoGenix rep

CytoSMART Technologies is to donate 100 mini live-cell imaging systems to researchers in high containment labs worldwide. Labs working to combat COVID-19 will benefit from this initiative, as CytoSMART aims to reduce the huge workload currently facing researchers on projects vital to controlling the disease. “We aim to do our part to assist researchers in minimizing the time they have to spend in high-contamination labs, by providing them with remote video access to evaluate t

Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) today announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133). Cefepime-taniborbactam is an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and